Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma
Official title: Precision next-generation radioimmunotherapies to Cure Non-Hodgkin Lymphoma
Funded at Washington University · NIH-11241103 · Data updated 2026-11-12
Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | December 5, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $645,156 |
| NIH project number | 5R01CA289487-02 |
| Project ID | NIH-11241103 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be people with CD20-positive B-cell non-Hodgkin lymphoma, especially those with relapsed disease or low-burden residual disease who are seeking new targeted options.
✕Less likely to help
Patients whose tumors do not express CD20, those with disease types unsuitable for targeted radioimmunotherapy, or those who cannot receive radiation or antibody treatments may not benefit.
What this research studies
If I had non-Hodgkin lymphoma, this project would be developing next-generation radioimmunotherapies that pair fully human anti-CD20 antibodies with more targeted radioactive particles to kill lymphoma cells while sparing healthy tissue. The team will run laboratory and animal experiments to compare different radioisotopes and delivery methods and build on earlier FDA-approved CD20 radioimmunotherapies. They will optimize dosing and radiation types better suited for low-burden or residual disease and address past practical and safety limitations. Promising candidates would then be moved toward early clinical testing in patients.
Why it matters
Potential benefit: If successful, this could raise cure rates and offer more effective, less toxic, and more accessible treatment options for people with CD20-positive NHL.
How similar studies have gone: Older CD20-directed radioimmunotherapies like Zevalin and Bexxar showed activity but had practical limits, and fully human, precision radioisotope approaches represent a newer, largely untested direction in patients.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Wahl, Richard Leo — Washington University
- Study coordinator: Wahl, Richard Leo
Related research
Other NIH-funded projects on the same topics.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)
Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.
-
New combination therapy for non-Hodgkin lymphoma
A virus-based combination treatment aims to boost the immune system to help people and companion dogs with relapsed or treatment-resistant diffuse large B-cell lymphoma.
-
New combination treatment for diffuse large B‑cell lymphoma
This project is trying a virus-based therapy together with checkpoint immunotherapy for people (and companion dogs) with relapsed diffuse large B‑cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.